Sort by:
ordered by relevance and dateSponsored Links
High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment
Web | www.medsci.org | Nov 19, 2009
If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment options, because prostate cancer is not very sensitive to cytostatic agents. Temozolomide (TMZ) as an orally applicable chemotherapeutic substance has been proven to be effective and well tolerated with
Agennix - Protein Therapeutics for Cancer and Diabetes
Agennix is a private biotechnology company developing a first-in-class molecule with activity in several types of cancer and in other indications with unmet medical needs. Talactoferrin is a targeted dendritic cell recruiter and activator (DCRA) with a novel mechanism of action.
Dose-dense chemotherapy in advanced ovarian cancer : The Lancet
News | www.thelancet.com
1 showing benefit from a dose-dense (once weekly) schedule of paclitaxel compared with standard dosing of once every 3 weeks in women with newly diagnosed epithelial ovarian, fallopian, or primary peritoneal carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61305-2
Datamonitor: Commercial Insight - Cytotoxic Therapies on reports-research.com
Press Release | www.prlog.org | Jul 13, 2009
Datamonitor: Commercial Insight - Cytotoxic Therapies on reports-research.com. Despite the advent of molecular targeted therapies, cytotoxic chemotherapy remains the cornerstone of cancer treatment and is used across nearly the entire spectrum of tumor types.
Targeted Therapies for Cancer: ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.
Optimum doses of irinotecan : The Lancet
Web | www.thelancet.com
Check ScienceDirect to see if you have access via your institution, or login with your Athens, Shibboleth or remote ScienceDirect username and password.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)75198-9
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Press Release | www.prnewswire.com | Oct 21, 2009
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer. - 28 of 46 (61%) Patients Receiving Bavituximab in Combination with Docetaxel Achieved Objective Tumor Response by End of Planned Treatment Cycles - - Tumor Response Data
Learn about the indication for ALlMTA in combination with cisplatin therapy for the initial...
Learn about the indication for ALlMTA in combination with cisplatin therapy for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. ALIMTA is not indicated for treatment of patients with squamous cell non-small cell lung cancer. ALIMTA.
ROCHE-layoutV2.indd
Web | medischcontact.artsennet.nl
Karolinska Institutet in collaboration with Stockholm School of Economics Stockholm, Sweden Foreword One of the great triumphs of scientific research has been to advance our knowledge of the causes and pathophysiology of malignancy.
CytRx, Cephalon Initiate Dose Escalation Study For Treatment Of APL - Pharmaceutical Business Review
News | www.pharmaceutical-business-review.com | Sep 14, 2009
CytRx has initiated dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX injection in patients with relapsed acute promyelocytic leukemia (APL). According to CytRx, there are two primary trial objectives.
